Why Psychedelics Could Soon Replace Antidepressants
Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults each year, and despite the abundance of antianxiety medications available, treatment resistance occurs in roughly 30% of patients. Anxiety ... [Read]
Demand for Toad Venom Rises Along With the Booming Psychedelics Market
Depression and anxiety affect millions around the world and the venom of a toad is the latest psychedelic compound being used as an alternative treatment. The Sonoran desert toad is the only animal on earth ... [Read]
Pharmacy Giant Files Patent to Join the Metaverse
The Metaverse could soon have its own pharmacy after CVS revealed its plans to sell virtual goods and provide healthcare services in the virtual world. As CNBC reported on March 4, the pharmacy giant filed ... [Read]
Psilocybin and MDMA Get the Green Light for Medical Use in Canada
After facing legal scrutiny for decades, psychedelics including MDMA and psilocybin received a stamp of approval from Health Canada for medical purposes. Canada’s legislation now permits the use of psychedelics beyond palliative care, something health ... [Read]
Purdue Pharma Explores Bankruptcy After Thousands of Lawsuits
OxyContin-maker Purdue Pharma LP is exploring bankruptcy to prepare for the thousands of lawsuits filed against the company, Reuters reported early this morning. An official statement has yet to be released by the private pharmaceutical company ... [Read]
JNJ Stock: Johnson & Johnson Misses Analyst Target for Forecast 2019 Sales
Johnson & Johnson (JNJ) (NYSE:JNJ) released its forecast 2019 sales earlier today. The pharmaceutical giant fell short of analyst estimates after previously reporting better-than-expected Q4 results. On the news, JNJ stock is down -2.06%, selling for ... [Read]
23andMe Gives Customer Data to GlaxoSmithKlein
23andMe launched a DNA testing service in 2007. Since then, more than 5 million people have used the genomics service to find out about their biological inheritance. With every application, 23andMe receives information about its ... [Read]
Teva Pharmaceutical Reports Drop in Q3 Profit, Shares Plunge Almost 18%
Now might not be the time to get into the drug manufacturers industry. Well, maybe just don’t invest in Teva Pharmaceutical Industries (NYSE:$TEVA) for the time being. On Thursday, after Teva Pharmaceutical – the biggest ... [Read]
3 Reasons Behind Celgene Corp.’s Abysmal Q3 Earnings Report
On Thursday, Celgene Corp. (NASDAQ:$CELG) reported its Q3 earnings report- and let’s just say it did not go nearly as well as we hoped. Missing revenue by a whopping $120 million, Celgene has since plummeted ... [Read]
Celgene Abandons Crohn’s Drug, Shares Drop to Four-Month Low
As of this morning, Celgene (NASDAQ:$CELG) shares have dropped to a four-month low, following scrapped trials in Crohn’s disease. Celgene shares plunged as much as 10.9%, near 122.40. Shares hit a low last seen in ... [Read]